- Genezen has announced a strategic manufacturing partnership with Atsena Therapeutics to support clinical development and commercial manufacturing of AAV-based gene therapies.
- The collaboration will support Atsena’s pipeline, including ATSN-201, which is being evaluated in a pivotal study for X-linked retinoschisis with a potential BLA filing targeted for early 2028.
Genezen has announced a strategic manufacturing partnership with Atsena Therapeutics, a clinical-stage gene therapy company focused on inherited retinal diseases. The collaboration aims to advance the clinical development and commercial manufacturing of Atsena’s pipeline programmes based on adeno-associated virus (AAV) technology.
Under the agreement, Genezen will use its viral vector manufacturing expertise to support both clinical and commercial supply using Atsena’s existing platform. The partnership is intended to provide a streamlined and cost-efficient route to commercial manufacturing, with Genezen supporting late-stage development through regulatory and validation readiness as a CDMO and contract manufacturing partner.
Atsena’s lead programme, ATSN-201, is being evaluated in the pivotal LIGHTHOUSE study for the treatment of X-linked retinoschisis. According to the announcement, the programme remains on track for a potential Biologics License Application filing in early 2028.
“With this strategic partnership, we will leverage our deep technical capability and commercial capacity to support Atsena’s pipeline programs.”
Steve Favaloro, Chairman and Chief Executive Officer of Genezen
